Streetbeat News

RYZB

RayzeBio Inc.

Industry

Research and Development in Biotechnology

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

AstraZeneca Plc (NASDAQ:AZN) has agreed to acquire Fusion Pharmaceuticals Inc (NASDAQ:FUSN) for $21.00 per share in cash, plus a contingent value right of $3.00 per share, totaling a potential $2.4 billion transaction. This acquisition signifies AstraZeneca's shift towards more targeted cancer treatments, specifically through radioconjugates (RCs), enhancing its oncology portfolio. The deal includes Fusion's cash assets and complements AstraZeneca's ambition to transform cancer treatment. Additionally, recent acquisitions by Bristol Myers Squibb & Co (NYSE:BMY) and Eli Lilly And Co (NYSE:LLY) highlight the industry's focus on targeted therapies.

Portfolio Pulse from Vandana Singh

March 19, 2024 | 11:26 am

Bristol Myers Squibb (BMY) and Rayzebio have announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, related to BMY's deal to acquire Rayzebio for $62.50 per share, announced on February 9.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 12:02 pm

Jim Cramer discussed various stocks on his show 'Mad Money', favoring Kellanova (K) over WK Kellogg Co (KLG) after their split. He prefers CarMax (KMX) and Lithia Motors (LAD) in the auto sector, and Wells Fargo (WFC) over Citigroup (C). He doesn't recommend tobacco stocks like Altria Group (MO) and is positive on General Electric (GE) for their aerospace work, preferring them over Boeing (BA). Cramer sees the opportunity in Palantir Technologies (PLTR) after a good quarter, is not optimistic about RayzeBio (RYZB), and likes Matador Resources (MTDR) but prefers Coterra Energy (CTRA).

Portfolio Pulse from Avi Kapoor

January 05, 2024 | 1:51 pm

The Global Data report indicates a decrease in pharma sector M&A deals in Q3 2023 compared to Q2 2023, with a 28% drop in deal value and a 9% drop in deal volume. However, PricewaterhouseCoopers forecasts a positive outlook for 2024, expecting a return to pre-pandemic levels of M&A activity. Notable deals in 2023 include acquisitions by Pfizer, Bristol Myers Squibb, Merck, AbbVie, Biogen, and Astellas Pharma.

Portfolio Pulse from Vandana Singh

December 29, 2023 | 12:04 pm

Fusion Pharmaceuticals Inc (FUSN) is highlighted as a key player in the targeted radiopharmaceutical therapy (TRT) space by Oppenheimer, especially after recent acquisitions by Bristol Myers Squibb & Co (BMY) and Eli Lilly And Co (LLY). Fusion's partnership with AstraZeneca Plc (AZN) on advancing targeted radiotherapies and a profit-sharing agreement could position AstraZeneca for future acquisitions. Raymond James upgraded Fusion's stock from Outperform to Strong Buy with a price target of $15.

Portfolio Pulse from Vandana Singh

December 27, 2023 | 5:42 pm

U.S. stocks closed higher with the Dow Jones rising over 150 points and the S&P 500 nearing record levels. Investor sentiment improved as indicated by the CNN Money Fear and Greed index remaining in 'Extreme Greed' territory. RayzeBio shares soared after a buyout announcement by Bristol Myers Squibb, and Gracell Biotechnologies shares surged following an acquisition agreement with AstraZeneca. All sectors of the S&P 500 ended positively, led by energy, real estate, and industrials. Investors are looking forward to Bridgeline Digital's earnings results.

Portfolio Pulse from Avi Kapoor

December 27, 2023 | 8:28 am

RayzeBio, Inc. (RYZB) shares surged 100% after announcing its acquisition by Bristol Myers Squibb for $62.50 per share in cash, valuing the deal at $4.1 billion. Other stocks also moved significantly in Tuesday's mid-day session, with ARB IOT Group Limited (ARBB) and IMAC Holdings, Inc. (BACK) among the top gainers, while PARTS iD, Inc. (ID) and Milestone Pharmaceuticals Inc. (MIST) were among the top losers.

Portfolio Pulse from Avi Kapoor

December 26, 2023 | 6:48 pm

In Tuesday's intraday session, several healthcare stocks experienced significant movements. RayzeBio (RYZB) saw a 100.8% increase to $61.4 with a market cap of $3.6 billion. IMAC Hldgs (BACK) rose 74.02% to $4.21, and Gracell Biotechnologies (GRCL) went up by 59.93% to $9.9. Conversely, Milestone Pharmaceuticals (MIST) dropped 32.3% to $1.95, ENDRA Life Sciences (NDRA) fell 22.01% to $1.95, and Jin Medical International (ZJYL) declined by 18.51% to $111.67.

Portfolio Pulse from Benzinga Insights

December 26, 2023 | 5:31 pm

William Blair analyst Andy Hsieh has downgraded RayzeBio (NASDAQ:RYZB) from Outperform to Market Perform, indicating a change in the firm's outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 26, 2023 | 3:41 pm

Bristol-Myers Squibb (NYSE:BMY) is set to merge with RayzeBio (NASDAQ:RYZB), with the deal expected to close in the first half of 2024. Bristol-Myers Squibb will acquire RayzeBio for $4.10 billion in cash. This strategic move will combine Bristol-Myers Squibb's expertise in drug development, particularly in immuno-oncology, with RayzeBio's focus on radiopharmaceutical therapeutics aimed at defeating cancer.

Portfolio Pulse from Benzinga Insights

December 26, 2023 | 3:10 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.